Tecrea Ltd is thrilled to announce that it has received funding from the Innovate UK Biomedical Catalyst to support the development of its novel antimicrobial therapy for recurrent urinary tract infections (UTIs). This funding marks a significant milestone in Tecrea’s mission to create a dual-action, non-antibiotic treatment that not only combats infection but also alleviates UTI symptoms through localized administration. The project builds on momentum from Tecrea’s successful participation in the Accelerating Femtech Accelerator programme.
UTIs are a global health concern, affecting an estimated 404.61 million people worldwide in 2019. In the UK alone, over 180,000 hospital admissions last year were UTI-related, with an annual cost of £604 million to the NHS. Approximately 60% of women will experience a UTI in their lifetime, and 20–30% of them will go on to suffer from recurrent infections.
Tecrea is proud to be at the forefront of this vital research and is committed to developing a solution that addresses the unmet needs of millions living with chronic UTIs.
The Biomedical Catalyst plays a crucial role in supporting UK SMEs in the health and life sciences sector, offering funding and resources to accelerate the development of innovative therapeutics, medical devices, and digital health solutions. By backing projects like Tecrea’s, it ensures that pioneering health technologies are developed, scaled, and retained within the UK.
Click here to read the Innovate UK Business Connect announcement.
This news post is for informational purposes only and does not constitute a formal publication or scientific endorsement of the technologies mentioned.